Document is current
Any future updates will be listed below
-
Authors
Zhang, Lianghui
Dutta, Soumajit
Xiong, Shiqin
Chan, Matthew https://orcid.org/0000-0002-9826-1983
Chan, Kui K.
Fan, Timothy M.
Bailey, Keith L.
Lindeblad, Matthew
Cooper, Laura M. https://orcid.org/0000-0002-6322-1260
Rong, Lijun
Gugliuzza, Anthony F.
Shukla, Diwakar
Procko, Erik https://orcid.org/0000-0002-0028-490X
Rehman, Jalees https://orcid.org/0000-0002-2787-9292
Malik, Asrar B. https://orcid.org/0000-0002-8205-7128
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL157489, P01-HL060678, R01-HL154538, R01-HL152515, P01-HL151327, P01-HL060678, R01-HL154538, T32-HL007829, P01-HL151327, R01-HL152515)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R43-AI162329, R43-AI162329)
C3.ai Digital Transformation Institute Research Award provided by C3.ai Inc. and Microsoft Corporation
University of Illinois College of Medicine intramural funds
- License Information
-
More Information
Article History
Received: 22 August 2021
Accepted: 16 December 2021
First Online: 19 January 2022
Competing interests
: L.Z., S.X., J.R., E.P. and A.B.M. are inventors on a patent filing by the University of Illinois covering the use of engineered polypeptides targeting coronaviruses. E.P. is a consultant and stockholder of Cyrus Biotechnology, which licenses the intellectual property.
